RadNet has acquired Gleamer, a Paris-based radiology AI company, which it will integrate into its AI subsidiary DeepHealth.
Under terms of the cash transaction -- valued at up to €230 million -- RadNet will incorporate Gleamer's portfolio of U.S. Food and Drug Administration (FDA)-cleared and CE-marked clinical AI and workflow software for musculoskeletal, breast, lung, and neurologic applications into DeepHealth, it said. Gleamer serves more than 700 customer contracts in 44 countries and achieved a compound annual growth rate in annual recurring revenue exceeding 90% from 2022 through 2025, according to RadNet. It is expected to reach approximately $30 million (€25.6 million) in annual recurring revenue in 2026, according to the firm.
The acquisition will expand DeepHealth's existing clinical AI portfolio, which covers breast, chest, neuro, prostate, and thyroid applications, RadNet said. The combined portfolio is intended to support screening, detection, interpretation, and follow-up across MRI, CT, x-ray, mammography, and ultrasound modalities.
Gleamer's capabilities in automated reporting, already implemented in Europe, combined with DeepHealth's informatics portfolio, are expected to enable draft reporting and scalable diagnostic pathways, according to the company. Deploying Gleamer's solutions across RadNet's imaging network -- where x-ray accounts for nearly 25% of imaging volume -- is expected to drive cost efficiencies by the third quarter of 2026.
